IL-22 Inhibitor

Fezakinumab (ILV 094) is an anti-IL-22 monoclonal antibody. Fezakinumab inhibits IL-22 signal transduction, and regulates the JAK1/STAT3 pathway as well as apoptotic proteins. Fezakinumab alleviates airway remodeling, alveolar enlargement and inflammatory cell infiltration in lung tissues. Fezakinumab reduces the levels of neutrophils, lymphocytes, eosinophils and macrophages in lung tissues. Fezakinumab can be used in the research of chronic obstructive pulmonary disease and skin diseases.

Temtokibart (ARGX-112) is a monoclonal antibody and also an IL-22RA1 inhibitor. Temtokibart inhibits the signal transduction of IL-22, IL-20 and IL-24. Temtokibart reduces the expression levels of inflammatory proteins, chemokines, immune cell migration and markers of activated immune pathways. Temtokibart improves the expression of genes related to immunity and epidermal barrier function. Temtokibart is applicable to research on moderate-to-severe atopic dermatitis.

Hesperetin 7-O-glucoside is a typical flavonoid monoglucoside, which is an anti-inflammatory agent and an antihypertensive with orally active. Hesperetin 7-O-glucoside is a commonly used food adjuvant. Hesperetin 7-O-glucoside inhibits human intestinal maltase and human HMG-CoA reductase with K_i of 1.8 mM and 9.8 μM, respectively. Hesperetin 7-O-glucoside has antibacterial activity and can regulate intestinal flora and metabolic homeostasis in mice.

PI3K/AKT/JAK2-IN-1 is a potent multi-target inhibitor of the PI3K/AKT/JAK2 signaling pathway. PI3K/AKT/JAK2-IN-1 suppresses NO production (IC₅₀ = 1.0 μM), reduces pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, IL-17A, IL-22), and inhibits keratinocyte hyperproliferation by downregulating Ki67 and PCNA. PI3K/AKT/JAK2-IN-1 can be used for psoriasis research.

APG-2305 is a selective IL-23 receptor inhibitor. APG-2305 inhibits IL-23-induced STAT3 phosphorylation, reduces the expression of pro-inflammatory cytokines (IL-1, IL-6, IL-22) without altering IL-17 levels, and alleviates inflammation in multiple in vivo models. APG-2305 is used for research on inflammatory autoimmune diseases.

PROTAC IRAK4 degrader-13 (Degrader 1) is a selective IRAK4 PROTAC degrader with DC₅₀s of 0.86 and 1.1 nM for monocytes and lymphocytes in PBMCs, respectively. PROTAC IRAK4 degrader-13 significantly induces TIR signal activation, and inhibits the expression of circulating proinflammatory cytokines in Imiquimod (HY-B0180) induced psoriasis mice model. PROTAC IRAK4 degrader-13 can be used for TLR- and IL-1R-driven driven neutrophilic inflammation diseases like hidradenitis suppurativa (HS) and atopic dermatitis (AD) research. Pink: IRAK4 ligand; Blue: E3 ligase ligand; Black: linker

Anti-CD1a Antibody (OKT-6) is an anti-human CD1a IgG1 monoclonal antibody. Anti-CD1a Antibody (OKT-6) blocks T cell activation by blocking CD1a function. Anti-CD1a Antibody (OKT-6) can reduce the production of IFN-γ. Anti-CD1a Antibody (OKT-6) can be used for researches on cancer and inflammation such as leukemia. The recommend isotype control of Anti-CD1a Antibody (OKT-6): Mouse IgG1 kappa, Isotype Control (HY-P99977).